Skip to content

Study · Randomized controlled trial · n = 100 · 2017

4 results

Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.

Dejgaard TF, Johansen NB, Frandsen CS, Asmar A, Tarnow L, Knop FK, Madsbad S, Andersen HU

Diabetes, obesity & metabolism19 Jan 2017Cited by 19 (Europe PMC)

PMID27935240 (opens in a new tab)DOI10.1111/dom.12841 (opens in a new tab)PepBankPUB-27935240
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In overweight adults with type 1 diabetes, liraglutide added to insulin increased 24-hour heart rate by 4.6 beats per minute versus placebo after 24 weeks.

    In plain wordsIn overweight adults with type 1 diabetes, liraglutide raised the 24-hour heart rate by 4.6 beats per minute compared with placebo.

    Peptide
    Liraglutide
    Outcome
    Increase24-hour heart rate
    Study

    n = 100

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg once daily · 24 weeksAs given in this study (human).

    Measurements

    24-hour heart rate difference
    4.6 BPM
    liraglutide vs placebo

    Source sentences

    Summary
    Compared with placebo, liraglutide increased 24-hour heart rate by 4.6 beats per minute (BPM); P = .0015
    1 context sentence
    Summary · context
    In total, 100 overweight (BMI ≥25 kg/m2 ) adult patients (age ≥18 years) with type 1 diabetes and HbA1c ≥ 8% (64 mmol/mol) were randomized to liraglutide 1.8 mg or placebo added to insulin treatment in a 24-week double-blinded, placebo-controlled trial.
  2. 02HumanRandomized controlled trialSafety outcome

    In overweight adults with type 1 diabetes, liraglutide increased daytime heart rate versus placebo after 24 weeks.

    In plain wordsIn overweight adults with type 1 diabetes, liraglutide raised the daytime heart rate compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseDaytime heart rate
    Study

    n = 100

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg once daily · 24 weeksAs given in this study (human).

    Measurements

    Daytime heart rate difference
    3.7
    liraglutide vs placebo

    Source sentences

    Summary
    daytime heart rate by 3.7; P = .0240 and night-time heart rate by 7.5 BPM; P < .001 after 24 weeks.
    1 context sentence
    Summary · context
    In total, 100 overweight (BMI ≥25 kg/m2 ) adult patients (age ≥18 years) with type 1 diabetes and HbA1c ≥ 8% (64 mmol/mol) were randomized to liraglutide 1.8 mg or placebo added to insulin treatment in a 24-week double-blinded, placebo-controlled trial.
  3. 03HumanRandomized controlled trialSafety outcome

    In overweight adults with type 1 diabetes, liraglutide increased night-time heart rate by 7.5 BPM versus placebo after 24 weeks.

    In plain wordsIn overweight adults with type 1 diabetes, liraglutide raised the night-time heart rate by 7.5 beats per minute compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseNight-time heart rate
    Study

    n = 100

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg once daily · 24 weeksAs given in this study (human).

    Measurements

    Night-time heart rate difference
    7.5 BPM
    liraglutide vs placebo

    Source sentences

    Summary
    night-time heart rate by 7.5 BPM; P < .001 after 24 weeks.
    1 context sentence
    Summary · context
    In total, 100 overweight (BMI ≥25 kg/m2 ) adult patients (age ≥18 years) with type 1 diabetes and HbA1c ≥ 8% (64 mmol/mol) were randomized to liraglutide 1.8 mg or placebo added to insulin treatment in a 24-week double-blinded, placebo-controlled trial.
  4. 04HumanRandomized controlled trialSafety outcome

    In overweight adults with type 1 diabetes, diastolic nocturnal blood pressure increased by 4 mm Hg with liraglutide compared with placebo.

    In plain wordsIn overweight adults with type 1 diabetes, night-time diastolic blood pressure rose by 4 mm Hg with liraglutide compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseDiastolic nocturnal blood pressure
    Study

    n = 100

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1.8 mg once daily · 24 weeksAs given in this study (human).

    Measurements

    Diastolic nocturnal blood pressure difference
    4 mm Hg
    liraglutide vs placebo

    Source sentences

    Summary
    Diastolic nocturnal blood pressure increased by 4 mm Hg; P = .0362 in the liraglutide group compared with placebo.
    1 context sentence
    Summary · context
    In total, 100 overweight (BMI ≥25 kg/m2 ) adult patients (age ≥18 years) with type 1 diabetes and HbA1c ≥ 8% (64 mmol/mol) were randomized to liraglutide 1.8 mg or placebo added to insulin treatment in a 24-week double-blinded, placebo-controlled trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.